CASE HUB ARCHIVED—this archived case hub reflects the position at the date of the decision of 18 December 2020; it is no longer maintained. See further, timeline commentary and related cases. Case facts Outline CMA Chapter II investigation into Essential Pharma in relation to an alleged abuse of dominance concerning its intention to withdraw the supply of Priadel, a lithium-based medication for the treatment of bipolar disease. Latest developments On 18 December 2020, the CMA announced that it had formally accepted commitments from Essential Pharma and had closed the case. Under the commitments, Essential Pharma will: (i) ensure appropriate and continued supplies of Priadel to the UK on terms agreed from time to time with the Department of Health and Social Care, (ii) not serve a discontinuation notice to the Department of Health and Social Care relating to Priadel, and (iii) ensure that the potential divestment of, or grant of a licensing agreement in relation to, the supply of Priadel in the UK does not affect the application of the proposed commitments.